When the gastrointestinal eosinophilia is limited to the esophagus and is accompanied by characteristic symptoms, it is termed eosinophilic esophagitis (EoE). EoE is an increasingly recognized cause of dysphagia and possibly heartburn that is unresponsive to antireflux measures., Learn more about DUPIXENT® (dupilumab), the first FDA-approved biologic to treat eosinophilic esophagitis (EoE) in adult and pediatric patients aged 1 year and older who weigh at least 33lb (15kg). Serious side effects can occur. Please see Important Safety Information and Prescribing Information and Patient Information on website., An overview of eosinophilic esophagitis (EoE) symptoms, diagnosis, treatment and management written by the leading experts in allergy, asthma and immunology., , , .